Tasly Pharmaceutical Group Co., Ltd

SHSE:600535 Stock Report

Market Cap: CN¥23.0b

Tasly Pharmaceutical Group Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jing Su

Chief executive officer

CN¥2.4m

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Apr 26
Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15
Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

CEO

Jing Su (60 yo)

no data

Tenure

CN¥2,430,400

Compensation

Mr. Jing Su is General Manager and Director of Tasly Pharmaceutical Group Co., Ltd.

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.